ArticleThe pharmacogenomics journal2002
Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study.
Article in The pharmacogenomics journal, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacological Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Anti-hypertensive Treatment
GenHAT - Genetics of Hypertension Associated Treatments - Ancillary to ALLHAT
Who cites it
29 citing papers in PubMed, 58 citations in OpenAlex.
- Trial
- The Interaction of a Diabetes Gene Risk Score With 3 Different Antihypertensive Medications for Incident Glucose-level Elevation.American journal of hypertension · 2019Trial
- Trial
- The effects of genes implicated in cardiovascular disease on blood pressure response to treatment among treatment-naive hypertensive African Americans in the GenHAT study.Journal of human hypertension · 2016Trial
- Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study.Pharmacogenetics and genomics · 2012Trial
- Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.PloS one · 2012Trial
- Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study.Journal of hypertension · 2010Trial
- Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.Pharmacogenetics and genomics · 2009Trial
- Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES).American heart journal · 2008Trial
- Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study.The pharmacogenomics journal · 2007Trial
- Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).Journal of clinical hypertension (Greenwich, Conn.) · 2006Trial
- Evaluation of functional annotation-informed and ancestry-specific polygenic risk scores for ischemic stroke.Frontiers in bioinformatics · 2026Article
- Single-Ancestry versus Multi-Ancestry Polygenic Risk Scores for CKD in Black American Populations.Journal of the American Society of Nephrology : JASN · 2024Article
- Variant level heritability estimates of type 2 diabetes in African Americans.Scientific reports · 2024Article
- Pharmacogenomics: current status and future perspectives.Nature reviews. Genetics · 2023Review
- Genome-wide polygenic score to predict chronic kidney disease across ancestries.Nature medicine · 2022Article
- Development and validation of a trans-ancestry polygenic risk score for type 2 diabetes in diverse populations.Genome medicine · 2022Article
- Article
- Hypertension genomics and cardiovascular prevention.Annals of translational medicine · 2018Review
- Research Needs to Improve Hypertension Treatment and Control in African Americans.Hypertension (Dallas, Tex. : 1979) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
The Genetics of Hypertension Associated Treatment (GenHAT) study will determine whether variants in hypertension susceptibility genes interact with antihypertensive medication to modify coronary heart disease (CHD) risk in hypertensives. GenHAT is an ancillary study of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial, ALLHAT, a double-blind, randomized trial of 42 418 hypertensives, 55 years of age or older, with systolic or diastolic hypertension and one or more risk factors for cardiovascular disease. About 50% are non-white, and about half are female. ALLHAT completes follow-up in March 2002. GenHAT is typing variants in hypertension genes; completion of genotyping is scheduled for 2003. Analysis of gene-treatment interactions in relation to outcomes include CHD, stroke, heart failure, and blood pressure lowering. To our knowledge, GenHAT is the largest pharmacogenetic study ever conducted. An added strength is its ability to link gene-treatment interactions with important clinical outcomes across diverse ethnic and gender groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.